Article
CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.
The British journal of ophthalmology - 1 Feb 2012
McKibbin Martin, Ali Manir, Bansal Shveta, Baxter Paul D, West Kumi, Williams Grange, Cassidy Frances, Inglehearn Chris F
Abstract excerpt
AIMS: To investigate an association between genotype for three single nucleotide polymorphisms strongly associated with the development of age-related macular degeneration (AMD) and the early response to treatment with intravitreal ranibizumab for neovascular AMD. METHODS: Best corrected visual acuity letter score was recorded at baseline and each subsequent visit. Age, sex, smoking history, lesion type and the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
